PAVmed IncNASDAQ:PAVMNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE1.9500
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.7839/ 1
- Ask / Lots3.1200/ 2
- Open / Previous Close0.0000 / 1.9500
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | PAVM |
|---|---|---|
| 09:32 ET | 1550 | 1.97 |
| 09:39 ET | 600 | 1.95 |
| 09:41 ET | 200 | 1.95 |
| 10:12 ET | 3540 | 1.95 |
| 10:14 ET | 2600 | 1.9598 |
| 11:15 ET | 110 | 1.95 |
| 11:27 ET | 200 | 1.95 |
| 11:38 ET | 200 | 1.9581 |
| 12:45 ET | 117 | 1.9506 |
| 01:01 ET | 379 | 1.95 |
| 01:03 ET | 200 | 1.95 |
| 01:17 ET | 800 | 1.95 |
| 01:24 ET | 200 | 1.925 |
| 01:37 ET | 100 | 1.95 |
| 02:24 ET | 5250 | 1.95 |
| 02:29 ET | 209 | 1.94 |
| 02:36 ET | 500 | 1.95 |
| 02:44 ET | 300 | 1.95 |
| 02:47 ET | 100 | 1.95 |
| 02:54 ET | 506 | 1.95 |
| 03:02 ET | 200 | 1.95 |
| 03:18 ET | 216 | 1.95 |
| 03:20 ET | 1000 | 1.95 |
| 03:23 ET | 100 | 1.95 |
| 03:25 ET | 300 | 1.95 |
| 03:30 ET | 350 | 1.95 |
| 03:38 ET | 100 | 1.95 |
| 03:54 ET | 4802 | 2.01 |
| 03:57 ET | 192 | 1.98 |
| 03:59 ET | 891 | 1.95 |
Apr 8, 2024
Lucid Diagnostics to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference, from 8:30AM ET on Monday Apr 08, 2024 by Dow Jones
8:30AM ET on Monday Apr 08, 2024 by Dow Jones
Mar 26, 2024
Press Release: PAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results, from 7:32PM ET on Tuesday Mar 26, 2024 by Dow Jones
7:32PM ET on Tuesday Mar 26, 2024 by Dow JonesPAVmed Provides Business Update and Fourth Quarter and Full Year 2023 Financial Results, from 7:32PM ET on Tuesday Mar 26, 2024 by Dow Jones
7:32PM ET on Tuesday Mar 26, 2024 by Dow Jones
Mar 21, 2024
Lucid Diagnostics Announces Positive Data from the First Prospective Clinical Validation Study of EsoGuard(R) Esophageal Precancer Testing in a Screening Population, from 9:30AM ET on Thursday Mar 21, 2024 by Dow Jones
9:30AM ET on Thursday Mar 21, 2024 by Dow JonesPAVmed Launches Incubator to Advance Existing Pipeline Technologies including PortIO, EsoCure and CarpX, from 8:30AM ET on Thursday Mar 21, 2024 by Dow Jones
8:30AM ET on Thursday Mar 21, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
PAVmed Inc | 17.9M | -0.2x | --- |
Akili Inc | 18.3M | -0.3x | --- |
BioSig Technologies Inc | 17.2M | -0.4x | --- |
QT Imaging Holdings Inc | 16.1M | -1.9x | --- |
BioElectronics Corp | 6.2M | -12.5x | --- |
Positron Corp | 28.7M | -12.8x | --- |
Company Information
PAVmed Inc. is a multi-product, commercial-stage medical technology company. The Company operates through three lines of business: Medical Devices, Diagnostics, and Digital Health. Its subsidiary includes Lucid Diagnostics Inc., which is a commercial-stage cancer prevention medical diagnostics company that markets the EsoGuard Esophageal DNA Test and EsoCheck Esophageal Cell Collection Device for early detection of esophageal precancer to prevent esophageal cancer deaths. EsoCheck is a noninvasive swallowable balloon capsule catheter device capable of sampling surface esophageal cells. EsoGuard is a bisulfite-converted next-generation sequencing (NGS) DNA assay performed on surface esophageal cells collected with EsoCheck. Its other subsidiary, Veris Health Inc., is focused on enhanced personalized cancer care through remote patient monitoring using implantable vascular access port with wireless communication combined with an oncologist-designed remote digital healthcare platform.
Contact Information
- Headquarters
- 360 Madison Avenue, 25Th FloorNEW YORK, NY, United States 10017
- Phone
- 212-949-4319
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Lishan Aklog
- President, Chief Financial Officer
- Dennis Mcgrath
- Independent Vice Chairman of the Board
- Michael Glennon
- President - Veris Health
- Gary Manning
- Chief Operating Officer, Executive Vice President
- Shaun O'Neil
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $17.9M |
|---|---|
Revenue (TTM) | $2.5M |
Shares Outstanding | 9.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.84 |
EPS | $-9.24 |
Book Value | $-6.28 |
P/E Ratio | -0.2x |
Price/Sales (TTM) | 7.3 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -2,959.95% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
